VILDADAC

Introduction:
The VILDADAC product line is a trusted range of oral antihyperglycemic agents featuring Vildagliptin, a potent DPP-4 inhibitor designed for the effective management of type 2 diabetes mellitus. By enhancing the body’s own incretin system, VILDADAC improves glycemic control without causing weight gain or significant hypoglycemia. Available in monotherapy and fixed-dose combination with Metformin, VILDADAC offers flexible treatment options based on clinical need. With premium ALU-ALU blister packaging (10 x 10 tablets), VILDADAC ensures excellent product stability, moisture protection, and consistent therapeutic efficacy.

Product Range & Benefits

VILDADAC

• Composition: Vildagliptin 50 mg

• Packaging: ALU-ALU, 10 x 10 Tablets

• Use: Ideal for monotherapy in newly diagnosed type 2 diabetes patients or as add-on therapy to Metformin, Sulfonylureas, Thiazolidinediones, or Insulin.

VILDADAC-M

• Composition: Vildagliptin 50 mg + Metformin 500 mg

• Packaging: ALU-ALU, 10 x 10 Tablets

• Use: Dual-action combination for enhanced glycemic control targeting both incretin hormones (DPP-4 inhibition) and hepatic glucose production (Metformin).

Indications:

• Type 2 diabetes mellitus (as monotherapy or combination therapy)

• Adjunct to diet and exercise to improve glycemic control

• In combination with Metformin, Sulfonylureas, Thiazolidinediones, or Insulin

• Patients with inadequate glycemic control on Metformin alone

• Elderly patients with type 2 diabetes (favorable safety profile)

• Patients with renal impairment (dose adjustment required)

Dosage and Administration:

• VILDADAC: One tablet (50 mg) once or twice daily (total 50-100 mg per day), with or without food.

• VILDADAC-M: One tablet twice daily with meals to reduce gastrointestinal side effects associated with Metformin.

• Dose adjustment required for moderate to severe renal impairment (eGFR based).

• Regular monitoring of HbA1c, fasting and postprandial blood glucose is recommended.

• Swallow whole with water; do not crush or chew.

Precautions & Warnings:

• Contraindicated in type 1 diabetes mellitus and diabetic ketoacidosis.

• Use cautiously in patients with renal impairment, hepatic impairment, or history of pancreatitis.

• Metformin-containing products (VILDADAC-M): Risk of lactic acidosis; monitor renal function before and during treatment.

• Discontinue immediately if symptoms of pancreatitis (severe abdominal pain radiating to the back, nausea, vomiting) occur.

• May cause angioedema or bullous pemphigoid (rare); discontinue if skin lesions, blisters, or swelling of face/lips/tongue appear.

• Not recommended during pregnancy and lactation unless clearly necessary.

• Monitor liver function tests before and during treatment (rare cases of hepatic dysfunction reported).

Drug Interactions:

• ACE inhibitors: Increased risk of angioedema

• NSAIDs, sulfonylureas, insulin: Increased risk of hypoglycemia

• Cationic drugs (cimetidine, amiloride, digoxin, morphine, procainamide, quinidine, quinine, ranitidine, triamterene, trimethoprim, vancomycin): May interact with Metformin component (VILDADAC-M)

• Alcohol: Increases risk of lactic acidosis (with Metformin component)

Possible Side Effects:

• Common: Headache, dizziness, nasopharyngitis, upper respiratory tract infection

• Gastrointestinal: Nausea, diarrhea, abdominal pain (more common with Metformin combination)

• Hypoglycemia (rare with monotherapy; increased risk when combined with sulfonylureas or insulin)

• Tremors, fatigue, arthralgia (joint pain)

• Rare but serious: Pancreatitis, angioedema, bullous pemphigoid, hepatitis

• Metformin-containing: Metallic taste, vitamin B12 deficiency (long-term use)

Conclusion:
The VILDADAC range – including VILDADAC (Vildagliptin 50 mg) and VILDADAC-M (Vildagliptin 50 mg + Metformin 500 mg) – provides flexible, effective, and well-tolerated solutions for managing type 2 diabetes. With its unique DPP-4 inhibition offering glycemic control without weight gain or significant hypoglycemia, Vildagliptin ensures consistent diabetes management. Whether initiating monotherapy or requiring dual-action combination therapy, VILDADAC delivers reliable glycemic control with premium ALU-ALU packaging.

If you’re looking to buy Vildagliptin and combination tablets online or for clinical use, trust the VILDADAC range for proven efficacy, consistent quality, and patient-friendly dosing.

Note : Always Consult a physician before taking any medication, and do not rely solely on this information for medical advice.

For more such product information and similar product category Diabetic

You can also contact us  https://diabetes-cardiac.com/contact-us/